A B S T R A CT A 21-yr-old woman with Turner's syndrome presented with signs and symptoms of acromegaly. The serum growth hormone (GH) (95±9.4 ng/ ml; mean±SEM) and somatomedin C (11 U/ml) levels were elevated, and an increase in GH levels after glucose instead of normal suppression, increase after thyrotropin-releasing hormone (TRH) administration instead of no change, and decrease after dopamine administration instead of stimulation were observed. The pituitary fossa volume was greater than normal (1,440 mm3) and the presence of a pituitary tumor was assumed. After tissue removal at transsphenoidal surgery, histological study revealed somatotroph hyperplasia rather than a discrete adenoma. Postoperatively, she remained clinically acromegalic and continued to show increased GH and somatomedin levels. A search was made for ectopic source of a growth hormonereleasing factor (GRF). Computer tomographic scan revealed a 5-cm Diam tumor in the tail of the pancreas. Following removal of this tumor, serum GH fell from 70 to 3 ng/ml over 2 h, and remained low for the subsequent 5 mo. Serum somatomedin C levels fell from 7.2 to normal by 6 wk postoperatively. There were no longer paradoxical GH responses to glucose, TRH, and dopamine. Both the medium that held the tumor cells at surgery and extracts of the tumor contained a peptide with GRF activity. The GRF contained in the tumor extract coeluted on Sephadex 
G-50 chromatography with rat hypothalamic GHreleasing activity. Stimulation of GH from rat somatotrophs in vitro was achieved at the nanomolar range, using the tumor extract.
The patient's course demonstrates the importance of careful interpretation of pituitary histology. Elevated serum GH and somatomedin C levels in a patient with an enlarged sella turcica and the characteristic responses seen in acromegaly to TRH, dopamine, and glucose do not occur exclusively in patients with discrete pituitary tumors and acromegaly. This condition can also occur with somatotroph hyperplasia and then revert to normal after removal of the GRF source. Thus, in patients with acromegaly a consideration of ectopic GRF secretion should be made, and therefore, careful pituitary histology is mandatory. Consideration for chest and abdominal computer tomographic scans before pituitary surgery, in spite of their low yield, may be justified.
INTRODUCTION
Acromegaly is usually associated with a pituitary tumor. Only nine previous cases of acromegaly associated with ectopic growth hormone-releasing factor (GRF)' secretion have been reported (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . These patients have presented, with one exception (7), either with the mass effects of their extrapituitary tumors or with metastases, and the diagnoses have been made in retrospect or even at postmortem examination (2, 3, 8, 9) .
We now report a young woman with Turner's syndrome and acromegaly. At transsphenoidal surgery an apparent pituitary tumor was removed. Histological examination, however, revealed somatotroph hyperplasia. Postoperatively the patient remained acromegalic. In a systematic search for an ectopic source of a GRF, a computer tomographic (CT) scan of the abdomen revealed a tumor in the tail of the pancreas. After successful removal of the tumor, the acromegalic syndrome resolved. The dynamics of growth hormone (GH) and prolactin secretion in this patient and characterization of the pancreatic tumor and the GRF are described.
METHODS

Case report
This 21-yr-old White woman was found to have Turner's syndrome at age 11 yr when she underwent correction of coarctation of the aorta and patent ductus arteriosus. Physical examination at that time revealed short stature (height age, 7 yr), mild webbing of the neck, a low posterior hairline, short broad hands with small hyperconvex fingernails, widely spaced nipples, an increased carrying angle at the elbow, and multiple pigmented cutaneous nevi. Bone age was 9 yr. Chromosomal karyotpye was 45 XO. Endocrine evaluation included the following: normal oral glucose tolerance; serum thyroxine (T4) 6 .2 gg/dl (normal 5.2-11.8); serum luteinizing hormone (LH) 25 mIU/ml (normal for prepubertal child <5); serum follicle-stimulating hormone (FSH) 138 mIU/ml (mean of five samples; normal for prepubertal child <5) and serum GH 0.9 ng/ml. To Endocrine evaluation before pituitary microsurgery confirmed acromegaly by elevated serum somatomedin C and GH concentrations. Basal serum prolactin levels were elevated (88±3 ng/ml; n = 10, mean±SEM). Basal serum GH levels through the day were elevated (95±9.4 ng/ml; n = 10, mean±SEM) and the GH concentrations increased paradoxically after oral glucose (Table I ).
The patient underwent transsphenoidal surgery and a large "tumor" was identified and removed. The patient made an uneventful recovery, but serum GH and somatomedin C levels remained elevated (Table I) . She (12) . Serum prolactin, and other circulating hormones were also measured by RIA using reagents purchased from commercial sources (12) . Serum somatomedin C was determined by the Nichols Institute (San Pedro, CA) using the method of Furlanetto et al. (13) .
Rat prolactin and GH were measured in the media from primary cultures of anterior pituitary cells by RIA using reagents kindly supplied by the Pituitary Hormone Distribution Program, NIADDKD. Rat prolactin and OH reference preparations RP-2 and RP-1, respectively, were used as standards. The intraassay variation was 3% for rat prolactin at 17 ng/ml and 3.5% for rat GH at 110 ng/ml.
Clinical studies
The clinical studies were performed at the Clinical Re- search Center of the University of Virginia and written informed consent was obtained. The TRH test was performed by withdrawing blood samples through the heparin-lock cannula at -30, -15, 0, 20, and 60 min for determination of serum GH, TSH, and prolactin. TRH (Relefact, Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ), 500 ug, was given intravenously as a bolus through the cannula immediately after the 0-min blood sample was withdrawn.
The OGTT was performed by withdrawing blood samples for determination of blood glucose and serum GH at -30, 0, 30, 60, 90, and 120 min. 100 g glucose was given by mouth immediately after the 0-min blood sample.
Control and dopamine infusions were performed on consecutive days. At 0700 h a heparin-lock cannula was inserted into an antecubital vein in each arm. One was used for the infusion and the other for sampling. Blood samples were drawn every 30 min from 0800 to 1800 h for determination of serum GH and prolactin concentrations. During the control study 5% dextrose in water was infused using a Harvard infusion pump (Harvard Apparatus Co., Inc., S. Natick, MA) at 0.9 ml/min for 8 h from 0800 to 1600 h. On the following day 5% dextrose was infused for 4 h from 0800 to 1200 h and dopamine (Intropin, Anar-Stone Laboratories, Inc., Mount Prospect, IL) at 4 gg/kg per min from 1200 to 1600 h.
Pathological studies
For light microscopy, pituitary tissue and the pancreatic tumor were fixed in buffered formalin and embedded in paraffin. Sections, 4-6-gm thick were stained with hematoxylin-eosin, hematoxylin-phloxin-saffron, periodic acidSchiff (PAS), and lead hematoxylin. The Gordon-Sweet silver technique was used to study reticulin fibers in the pituitary and the Grimelius method for the demonstration of argyrophil granules in the pancreatic tumor. The immunoperoxidase technique, as described elsewhere (14) , was used to detect GH, prolactin, FSH, and LH in the pituitary tissue, and insulin, glucagon, somatostatin, gastrin, calcitonin, ACTH 1-39, GH, prolactin, and neuron-specific enolase in the pancreatic tumor. For electron microscopy, small pieces of tissue from the pituitary and pancreatic tumor, respectively, were fixed in glutaraldehyde, postfixed with osmium tetroxide, dehydrated in graded concentrations of ethanol, and embedded in epoxy resin. Ultrathin sections were stained with uranyl acetate and lead citrate.
Bioassays for GRF activity
Rat anterior pituitary primary culture. This was performed by a modification (15) 37°C atmosphere with 95% air and 5% CO2 before an experiment was performed. Immediately before a study, the cells were washed four times with serum-free RPMI 1640 medium with gentamicin to remove serum and previously secreted hormone. The control or test substances were diluted in a final volume of 2.3 ml of serum-free medium per well and 300-,ul aliquots were removed at 4 h for RIA of rat anterior pituitary hormones.
Human tumor-containing medium. Immediately following removal of the pancreatic tumor the tissue was sectioned into smaller pieces of -1 g each. These were placed into sterile RPMI 1640 medium supplemented with 10% horse serum, 2.5% fetal calf serum, 25 mM HEPES, and antibiotics (hereafter called the "tumor medium"). Control medium contained the same constituents, but was never exposed to the tumor. These media were aliquoted and stored at -80°C until immediately before the bioassay.
Extraction and chromatography of tumor. 2.5 g of the tumor as lyophilized, minced in a Polytron apparatus (Brinkmann Instruments, Inc., Westbury, NY) in 10 vol acetone, maintained at -20°C for 2 d and centrifuged. The acetone precipitate was extracted in hot (>90°C) 10% formic acid containing 10 mM EDTA and 0.5% f,-mercaptoethanol, for 2 min, dispersed with the Polytron, chilled, and centrifuged. The supernatant was defatted by three X 4 vol of ether/petroleum ether (1:2) and applied to a 3.5 X 120-cm column of Sephadex G-50 (fine) and eluted with 3 N acetic acid, 0.5% p3-mercaptoethanol at a flow rate of 20 ml/h. Fractions (9.4 ml) of eluate were collected, assayed for peptide content by the Bio-Rad protein assay (Bio-Rad Laboratories, Richmond, CA) (17), lyophilized, and bioassayed in pools for their ability to stimulate immunoreactive GH secretion by rat anterior pituitary primary cultures as described by Vale et al. (16) .
RESULTS
Hormonal evaluation
GH concentrations were measured retrospectively in basal serum samples that had been stored at -20°C for up to 10 yr (Table II) . GH levels were clearly elevated for >4 yr before the diagnosis of acromegaly. In Table III the results of other endocrine testing before, following pituitary microsurgery, during bromocriptine therapy, and after removal of a pancreatic (0), and 17 wk after removal of GRF-secreting pancreatic tumor (0). The rise of GH in response to TRH was observed before and after pituitary surgery. However, after removal of the GRF-secreting tumor basal GH levels were lowered to <10 ng/ml and the paradoxical increase of GH to TRH was abolished.
tumor are summarized. Basal serum prolactin levels were elevated (88±3 ng/ml; n = 10, mean±SEM). TRH, 500 ,g i.v., stimulated GH (Fig. 1) (Fig. 2) .
Serum GH decreased from 95±9.4 ng/ml preoperatively to 14 ng/ml at 6 and 12 h after transsphenoidal surgery, but rose to 35, 51, and >70 ng/ml at 25, 45, and 72 h postoperatively and remained elevated. At 7 wk postoperatively the serum GH and somatomedin C levels remained elevated (Table I ). The patient was treated with bromocriptine (2.5 mg q.i.d.) and the GH levels through the day (n = 10, mean±SEM) before, at 7 and 17 wk during, and 2 wk after withdrawal were 77±8.4, 56±3.3, 71±8.4, and 62±10.7 ng/ml, respectively, and the serum prolactin concentrations were 32±1, 2±0.3, 3±0.4, and 21±1.3 ng/ml. Thus, bromocriptine suppressed the serum prolactin, but not the GH concentrations. Serum somatomedin C concentrations were unchanged (Table I ). The paradoxical GH stimulation to glucose and TRH persisted (Tables   I and III GH decreased over 2 h from 70 to 3 ng/ml, although there was little change in serum prolactin (Fig. 3 ). 6 and 17 wk postoperatively the serum somatomedin C level fell from a preoperative level of 8.6 U/ml to 1.2 U/ml and 0.8 U/ml, respectively. Similarly, GH concentrations throughout the day (mean±SEM, n = 10) decreased from 62±10.7 ng/ml to 4±0.3 ng/ml and 6±0.8 ng/ml at 6 and 17 wk postoperatively. The GH response to glucose remained abnormal up to 17 wk postoperatively, since the serum GH concentration did not suppress to <2 ng/ml (Table I) . However, during a 4-h dopamine infusion the paradoxical suppression of GH was absent, and there was a rise of GH from 3 to 10 ng/ml at 30 min after the commencement of the infusion (Fig. 4) , and the paradoxical stimulations of GH to glucose and TRH (Fig. 1) were also absent (Tables I and III) .
Light microscopic, immunocytologic, and electron microscopic studies
Morphologic features of the pituitary. By light microscopy, no tumor was identified. The adenohypophysis was composed predominantly of well-differentiated, densely granulated acidophilic cells arranged in large nests (Fig. 5a ) that contained GH in their cytoplasm, as demonstrated by the immunoperoxidase technique (Fig. 5b) . Many prolactin cells (Fig. 5c ) and a few PAS-positive cells were randomly intermingled with the somatotrophs. Gonadotrophs were sparse and inconspicuous. No pleomorphism was noted nor were mitotic figures seen. The individual acini surrounded by reticulin fibers were larger than in the normal ad- HOURS AFTER TUMOR REMOVAL FIGURE 3 Serum GH and prolactin levels during and after removal of pancreatic tumor secreting GRF. Note the rapid fall of GH levels with no fall of prolactin levels following removal of the tumor. The base line is the mean of samples withdrawn during a 4-h control infusion. One study was performed before pituitary surgery when the mean serum GH (±SEM) was 124±17 ng/ml, and serum prolactin 83±2 ng/ml (these data are also shown in Fig. 2 (Fig. 6) . In some areas, the reticulin fibers were irregular or unusually well developed.
By electron microscopy, the overwhelming majority of cells were densely granulated somatotrophs. The nuclei were spherical or oval and contained prominent nucleoli. In the cytoplasm, the rough-surfaced endoplasmic reticulum (RER) membranes were moderately developed and consisted of slightly dilated parallel stacks studded with ribosomes on the external aspects. The Golgi complexes were conspicuous with the presence of numerous forming granules in the sacculi. The mitochondria were rod shaped, possessed lamellar cristae and a moderately electron dense matrix. The secretory granules were numerous, spherical or slightly irregular, evenly electron dense, and measured 200-600 nm in diameter. No exocytoses were seen. Lysosomes were inconspicuous. The fine structural features of the somatotrophs, except for the striking prominence of Golgi complexes, were similar to those seen in nontumorous adenohypophysis. Ladtotrophs and a few corticotrophs, gonadotrophs, and thyrotrophs were interspersed among the GH cells. The gonadotrophs 9.. The immunoperoxidase method revealed strong cytoplasmic positivity for neuron-specific enolase, supporting the islet cell origin of the tumor (18) . Immunostaining was negative for gastrin, insulin, glucagon, ACTH 1-39, calcitonin, GH and prolactin, and was inconclusive for somatostatin.
By electron microscopy, the tumor was composed of elongated, closely apposed cells with oval or irregular nuclei and prominent nucleoli (Fig. 7) . The cytoplasm was well developed and contained many RER profiles which, in some cells, formed fingerprint configurations (Nebenkerns). In some cells, the RER was unevenly dilated. The Golgi complexes were prominent. Some Golgi sacculi showed cystic dilatation, while others were flattened and contained a few immature secretory granules. The mitochondria were numerous, oval, or rod shaped with tubular cristae and electron dense matrix. The secretory granules varied widely in number and slightly in electron density from cell to cell; they measured 100-250 nm in diameter, the majority being -150 nm. Lysosomes were inconspicuous. Between adjacent cells, desmosomal attachments were noted. In some areas, regressive changes, representing degeneration and necrosis of cells, were apparent. Focal calcification was seen in cell debris and extracellular spaces.
In summary, this tumor appeared to be of endocrine nature and to have arisen from the pancreatic islet cells. The morphologic features of the tumor cells differed from those of nontumorous islet cells. Hence, the cell type constituting the tumor could not be defined.
GRF activity in the tumor medium
The medium that held the human pancreatic tumor after surgery contained substance(s) that stimulated the release of rat GH from primary cultures of rat anterior pituitary cells (Table IV) . By 4 h, a 1:10 dilution of the tumor medium had stimulated rat GH release sevenfold over that of cells exposed to the control medium. By contrast, there was no apparent effect on prolactin release by the tumor medium at 4 h.
Chromatography and biological activity of extract of pancreatic tumor Sephadex G-50 chromatography of the tumor extract was performed. GH releasing activity was detected in fractions 47-54 (Fig. 8) corresponding to KD values of 0.27-0.39. The extraction and chromatography of rat hypothalamic fragments by similar methods has resulted, in the detection of GH-releasing ac- somatotroph hyperplasia found. We submit that the diagnosis of somatotroph hyperplasia is justified in this patient, because no circumscribed mass was evident; the somatotrophs were very numerous but were intermingled with other adenohypophysial cell types; neither a pseudocapsule nor compression of surrounding tissue was present; and the reticulin network was preserved.
Both of the recently documented cases of somatotroph hyperplasia have been due to extrapituitary tumors, which have been shown, either definitively or presumptively, to secrete a GRF (8, 10) . Other cases of ectopic GRF secretion have been associated with either presumed or proven somatotroph adenoma. These GRF-secreting tumors have included islet cell tumors of the pancreas and carcinoid tumors (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) .
On the basis of the continued signs, symptoms, and biochemical evidence of acromegaly following transsphenoidal surgery, along with the pituitary histology, we made a search for a GRF-secreting tumor. The location and histology of the pancreatic tumor suggested that it originated in the islet cells and could be classified as neuroendocrine in origin, based on the presence of neuron-specific enolase immunostaining (18) . That this tumor secreted a GRF was confirmed by reduction of GH levels within minutes of tumor removal, with persistently normal GH levels postoperatively; the finding of GRF-like activity in the extract of the tumor; and the in vitro secretion of a product with GRF-like activity by tumor cells in culture (26) . Because no RIA for GRF is currently available, we were unable to demonstrate an arteriovenous gradient for GRF across the tumor bed. Furthermore, the GH levels measured on the stored samples suggested that our patient had GH hypersecretion for at least 4 yr before the diagnosis of acromegaly was established.
GH secretion is under dual hypothalamic control consisting of tonic inhibition and stimulation by somatostatin and GRF, respectively. Somatostatin was described in 1968 (27) and its structure reported in 1973 (28) . In 1960 Reichlin (29) (30) first proposed the existence of a GRF in the hypothalamus. Deuben (37, 38) , while our GRF extract demonstrated a dose-related increase in activity from 2 to 66 ng peptide/ml incubation medium, which suggests that it is active in the nanomolar range (Fig. 8) (39, 40) (Fig. 8) .
Hyperprolactinemia was present with somatotroph hyperplasia and no demonstrable pituitary tumor. The cause of the hyperprolactinemia is unknown; it is unlikely to have been due to an oral contraceptive preparation or to hypothyroidism (the patient was on thyroid replacement with normal serum thyroxine concentrations). Since there was no decrease in prolactin compared with GH levels after the removal of the pancreatic tumor, it is unlikely that this GRF is also a prolactin-releasing factor.
The paradoxical stimulation of GH secretion by glucose and TRH and the suppression of GH by dopamine are considered to be characteristic responses of a majority of tumors in acromegalic patients. It has been suggested that these responses to TRH and dopamine represent dedifferentiation of the somatotrophs (41) (42) (43) (44) , but this may not be correct. This patient offered us the opportunity to evaluate the importance of stimulation of the pituitary by GRF on these responses. These abnormal responses disappeared when the source of GRF was removed; thus, they are probably due to either the GRF/somatostatin input or the primary increased GH secretion rate, rather than to cellular dedifferentiation (not apparent on histopathology).
After removal of the GRF-secreting pancreatic tumor, GH levels fell from 70 to 3 ng/ml. However, at 6 and 17 wk postoperatively, GH levels during OGTT did not suppress to <2 ng/ml. In spite of the failure to suppress, serum somatomedin levels fell progressively to 1.2 U/ml and 0.8 U/ml at 6 and 17 wk, respectively. The continued hypersecretion of GH may reflect a resetting of the hypothalamus due to prolonged feedback of somatomedin C and/or GRF. Although at first consideration, suppression of GH secretion might be anticipated, the dual control of GH secretion by GRF and somatostatin may result in unpredictable changes in their release and thus of GH. Therefore, a considerable time may be needed for the normal control to be restored, in the same manner as the hypothalamic-pituitary-adrenal axis often requires many months to recover following removal of an ACTH-secreting tumor (45) . Willemse (46) reported acromegaly in a young woman with Turner's syndrome who had been treated with estrogens to promote linear growth. At surgery a pituitary tumor was removed. In our patient we believe that acromegaly and Turner's syndrome are coincidental. In this patient GH hypersecretion was documented together with extremely high somatomedin C levels and this was associated with the acromegalic features of increased hand and shoe size and changes in facial features. These biochemical and clinical signs regressed when the pancreatic GRF-secreting tumor was removed. Thus, at least the soft tissues are able to respond to pathologically elevated levels of GH and somatomedin C.
In our patient the pituitary enlargement was due to the somatotroph hyperplasia. Thus, the radiological evaluation was not helpful in distinguishing hyperplasia from pituitary tumor. None of the available tests for GH secretion is specific for a GH-secreting pituitary adenoma.
Our experience with this patient highlights the importance of proper pituitary histology to distinguish hyperplasia from adenoma. Ideally, this condition should be diagnosed before pituitary surgery. However, none of the radiological or dynamic endocrine tests performed currently are able to distinguish the acromegalic patient with a pituitary adenoma from that with a GRF-secreting tumor. If the incidence of GRF-secreting tumors is <1% of patients with acromegaly, routine body CT scans to diagnose these tumors may not be considered cost effective, although intellectually satisfying. Ultimately, the characterization of GRF and the development of a RIA for GRF may enable these patients to be diagnosed by simple blood tests. In such patients, a thorough search to identify any ectopic GRF-secreting tumor is mandatory.
Note added in proof. The GRF extracted and purified from this pancreatic tumor has been sequenced by Drs 
